Furthermore, tuberculosis reactivation via the “awakening” of dormant Mycobacterium tuberculosis has been linked to use of the JAK3/2 inhibitor tofacitinib (Maiga et al., 2015; Winthrop et al., 2016). Here, JAK3 is linked to tuberculosis.